Advertisement

Topics

Analysts' Weekly Ratings Changes for Teva Pharmaceutical Industries Limited

12:23 EDT 31 Jul 2017 | Topix

We are impressed by DSMB stoppage of a trial with less than half of patients enrolled suggesting a dramatic clinical benefit vs. standard of care. We believe today's news provides a favorable setup for the August 21 PDUFA for Vabomere in cUTI.

Original Article: Analysts' Weekly Ratings Changes for Teva Pharmaceutical Industries Limited

NEXT ARTICLE

More From BioPortfolio on "Analysts' Weekly Ratings Changes for Teva Pharmaceutical Industries Limited"

Quick Search
Advertisement